MedTrace Logo

sPLA2 in EBC During Acute Chest Syndrome

NCT03250585 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 6

Last updated 2018-09-26

No results posted yet for this study

Summary

Secretory phosholipases A2 (sPLA2) are significantly elevated in the plasma of sickle cell disease patients with acute chest syndrome (ACS), and similar enzymes have been measured in exhaled breath condensate (EBC), which is collected easily and non-invasively. The investigators hypothesize that sPLA2 will be measurable in EBC samples from sickle cell patients with acute chest syndrome.

Conditions

Interventions

DIAGNOSTIC_TEST

Exhaled Breath Condensate (EBC)

Serial EBC samples will be collected within 48 hours of acute chest syndrome (ACS) diagnosis and at 2 week follow up

DIAGNOSTIC_TEST

Plasma Sample

Serial plasma samples will be collected within 48 hours of acute chest syndrome (ACS) diagnosis and at 2 week follow up

Sponsors & Collaborators

  • Virginia Commonwealth University

    lead OTHER

Principal Investigators

  • Davis D Michael, PhD · Virginia Commonwealth University

Eligibility

Min Age
7 Years
Max Age
30 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-01-19
Primary Completion
2018-06-14
Completion
2018-06-14

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03250585 on ClinicalTrials.gov